Pilot study to evaluate glycemic control with GlucoTab using an ultra-long acting insulin analogue in non-critically ill patients with type 2 diabetes at the genaral ward - GlucoTab_Degludec

Medical University of Graz0 个研究点目标入组 30 人开始时间: 2018年8月10日最近更新: 2021年12月21日

适应症

试验速览

暂无简介。

•Informed consent obtained after being advised of the nature of the study
•Male or female aged =18 years
•Type 2 diabetes (treated with diet, oral agents, non-insulin injected anti-diabetic medicine, insulin therapy or any combination of the four) or newly diagnosed hyperglycemia which requires s.c. insulin therapy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Type 1 diabetes, gestational diabetes
•Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient
•continuous subcutaneous insulin infusion (CSII)
•hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
•Any mental condition rendering the patient incapable of giving his consent
•Known or suspected allergy to insulin degludec or insulin aspart
•Continuous parenteral nutrition
•Participation in another trial which can influence outcome of the trial

发起方

Medical University of Graz